Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5428074 | 0.99 | F10 (1.00) | F10 | |
| SCHEMBL9976490 | 0.93 | F10 (0.87) | F10 | |
| SCHEMBL5396391 | 0.93 | F10 (0.86) | F10 | |
| SCHEMBL9979805 | 0.91 | F10 (0.83) | F10 | |
| SCHEMBL9976489 | 0.90 | F10 (1.00) | F10 | |
| SCHEMBL9976508 | 0.89 | F10 (0.80) | F10 | |
| SCHEMBL9976507 | 0.88 | F10 (0.78) | F10 | |
| SCHEMBL5394524 | 0.87 | F10 (1.00) | F10 | |
| SCHEMBL9976496 | 0.84 | F10 (0.72) | F10 | |
| SCHEMBL8131344 | 0.82 | F10 (0.70) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | claimed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | claimed |
| EP-1415990-B1 | Diazepan derivatives useful as factor X inhibitor | ASTELLAS PHARMA INC (JP) | 2006-09-20 | — | — | EP | claimed |
| EP-1415990-A1 | Diazepan derivatives useful as factor X inhibitor | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| US-20040068109-A1 | Diazepan derivatives or salts thereof | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | claimed |
| US-20030195193-A1 | Diazepane derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2003-10-16 | — | — | US | claimed |
| EP-1273575-A1 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-08 | — | — | EP | claimed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| EP-1415990-B1 | Diazepan derivatives useful as factor X inhibitor | ASTELLAS PHARMA INC (JP) | 2006-09-20 | — | — | EP | disclosed |
| EP-1415990-A1 | Diazepan derivatives useful as factor X inhibitor | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040068109-A1 | Diazepan derivatives or salts thereof | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
| US-6642224-B1 | Diazepan derivatives or salts thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030195193-A1 | Diazepane derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1273575-A1 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195193-A1 | Diazepane derivatives or salts thereof | F10, F11, SERPINC1 | F10 1/4885 |
| US-20040068109-A1 | Diazepan derivatives or salts thereof | F10, SERPINC1, F11 | F10 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.